Asthma Therapeutics Market Size & Growth Analysis to 2030

The global asthma therapeutics market size was accounted for around USD 16 billion in 2019 and projected to grow at a significant CAGR of 6 % market during the forecast period 2020-2027. Asthma is a chronic respiratory disease mainly resulting from lower respiratory tract infection; its disease etiology is characterized by wheezing, coughing, breathlessness, and chest tightness. The causative agent for asthma can be genetic or environmental factors. There is no cure for asthma; however, it can be controlled and managed by using different medications.

Market Insights:

Rising asthma prevalence and increasing environmental pollution are the key growth factors in the asthma therapeutics market. In the base year 2019, combination therapy accounted for the largest market share in the drug class segment as the first line of treatment for asthma treatment is inhaled corticosteroids (ICS) with long-acting beta-agonists (LABA). The driving factors of this market are the rising prevalence of asthma and growing patient compliance. Metered-dose inhalers held the largest market in the product segments due to factors such as immediate relief from an asthma attack, controlled dose, and direct release of drugs in the respiratory system. Inhalation dominates the route of administration segment chiefly due to factors such as the rapid onset of action, less systemic toxicity, and higher concentration availability at the site of action.

The asthma therapeutics market is currently dominated by North America due to the increasing number of patients suffering from asthma, raising public awareness regarding asthma and early treatment, and supportive reimbursement policies. On the other hand, Asia Pacific is anticipated to be the fastest-growing market because of deep market penetration due to the increasing prevalence of asthma rapid industrialization causing increased air pollution, growing disposable income, and developing healthcare infrastructure.

Market Segment Insights:

The global asthma therapeutics market is majorly segmented into drug classes such as bronchodilators and anti-inflammatories, and combination therapy. The products segment comprises dry powder inhalers, metered-dose inhalers (MDIs), mist inhalers, and nebulizers. In terms of route of administration, this market is further sub-segmented as inhalation, oral and parenteral drugs. Combination therapy held the largest market share in the drug class segment due to factors such as the rising prevalence of asthma and patient compliance. Metered-dose inhalers lead the product segment due to factors such as immediate relief in asthma attacks and consistent drug delivery. The inhalation segment dominated the market in terms of route of administration due to factors such as the faster onset of action, better pharmacodynamics, and pharmacokinetic results achieved in asthma treatment.

Global Asthma Therapeutics Market Segmentation:

By Drug Class, 2018–2027 ($ Million)

• Anti-inflammatory drugs
• Bronchodilators
• Combination therapy

By Product, 2018–2027 ($ Million)

• Dry Powder Inhalers (DPI)
• Metered Dose Inhalers (MDI)
• Mist Inhaler
• Nebulizer

By Route of Administration, 2018–2027 ($ Million)

• Inhalation
• Oral
• Parenteral

By Geography, 2018-2027 ($ Million)

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

Regional Insights:

North America, Latin America, Europe, Middle East and Africa, and Asia Pacific, markets together form the major regional markets for asthma therapeutics. These regional markets are further sub-segmented into country-specific markets on the basis of demand and market growth of asthma therapeutics. Among the considered regional markets, North America currently dominates the global asthma therapeutics market, with the United States being the largest county-level market due to an increase in the number of patients suffering from asthma, early disease diagnosis and treatment, and supportive reimbursement policies. On the other hand, Asia Pacific is anticipated to be the fastest-growing market for asthma therapeutics due to the huge population base suffering from asthma, rapid industrialization causing increasing air pollution and high disposable income.

Market Competition Assessment:

Key players in the global asthma therapeutics market are Abbott Laboratories, AstraZeneca, Becton, Dickinson and Company, Boehringer Ingelheim GmbH, Chiesi Farmaceutici, F. Hoffmann-La Roche, GlaxoSmithKline Plc., Merck& Co., Inc., Pfizer, Philips Healthcare, Sanofi-Aventis SA, Sunovion Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd. and others.

List of Key Companies:

• Abbott Laboratories
• AstraZeneca
• Becton, Dickinson and Company
• Boehringer Ingelheim GmbH
• Chiesi Farmaceutici
• Hoffmann-La Roche
• GlaxoSmithKline Plc.
• Merck& Co., Inc.
• Pfizer
• Philips Healthcare
• Sanofi-Aventis SA
• Sunovion Pharmaceuticals, Inc.
• Teva Pharmaceutical Industries Ltd.

Key Questions Answered by Asthma Therapeutics Market Report

• Global asthma therapeutics market forecasts from 2020-2027
• Regional asthma therapeutics market forecasts from 2020-2027 covering Asia-Pacific, North America, Europe, Middle East and Africa, and Latin America
• Country level forecasts from 2020-2027 covering 15 major countries from aforementioned regions
• Asthma Therapeutics submarket forecasts from 2020-2027 covering the market by drug class, by product, by route of administration, and geography
• Various industry models such as SWOT analysis, Pestle Analysis, Porter’s Five Force model, Value Chain Analysis pertaining to the asthma therapeutics market
• Analysis of the key factors driving and restraining the growth of the global, regional and country-level asthma therapeutics markets from 2020-2027
• Competitive Landscape and market positioning of top 10 players operating in the asthma therapeutics market

Request a full report sample to review @ https://www.researchcorridor.com/request-sample/?id=18943